|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Minnesota - Clinical and Translational Science Institute |
|---|---|
| Information provided by (Responsible Party): | Jon E. Grant, University of Minnesota - Clinical and Translational Science Institute |
| ClinicalTrials.gov Identifier: | NCT00354770 |
Purpose
This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania
| Condition | Intervention | Phase |
|---|---|---|
|
Trichotillomania |
Drug: N-Acetyl Cysteine Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania |
| Enrollment: | 50 |
| Study Start Date: | July 2006 |
| Study Completion Date: | September 2008 |
| Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
N-Acetyl Cysteine
|
Drug: N-Acetyl Cysteine
daily
|
|
Placebo Comparator: 2
Placebo
|
Drug: Placebo
daily
|
The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in trichotillomania. Forty subjects with DSM-IV trichotillomania will receive 12 weeks of double-blind NAC or placebo. The hypothesis to be tested is that NAC will be effective and well tolerated in patients with trichotillomania compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Minnesota | |
| University of Minnesota Medical Center | |
| Minneapolis, Minnesota, United States, 55454 | |
| Principal Investigator: | Jon E Grant, MD, JD | University of Minnesota - Clinical and Translational Science Institute |
More Information
| Responsible Party: | Jon E. Grant, Professor of Psychiatry, University of Minnesota - Clinical and Translational Science Institute |
| ClinicalTrials.gov Identifier: | NCT00354770 History of Changes |
| Other Study ID Numbers: | 0604M85110 |
| Study First Received: | July 18, 2006 |
| Last Updated: | February 1, 2012 |
| Health Authority: | United States: Institutional Review Board |
|
Trichotillomania Hair-pulling |
|
Trichotillomania Impulse Control Disorders Mental Disorders Acetylcysteine N-monoacetylcystine Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes |